Comparing Thoracolumbar Interfascial and Quadro Iliac Plane Blocks on Postoperative Opioid Use Following Lumbar Microsurgery

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-80
SponsorMedipol University

About this trial

Lumbar microdiscectomy is a commonly used surgical procedure for treating herniated discs. Effective postoperative analgesia is crucial for early mobilization and functional recovery. Uncontrolled postoperative pain can delay recovery, increase the risk of opioid dependence, and lead to respiratory complications.

Although opioid analgesics effectively reduce pain, they can cause side effects such as nausea, vomiting, respiratory depression, and dependency. Therefore, non-opioid analgesic methods are preferred for patient safety and comfort. Recently, regional anesthesia techniques such as the Thoracolumbar Interfascial Plane (TLIP) block and the Quadro Iliac Plane Block have been introduced for postoperative pain management in lumbar surgeries. However, there are not enough studies comparing the superiority of these two methods.

Study Objective: The primary aim of this study is to evaluate the effects of ultrasound-guided TLIP and Quadro Iliac Plane Blocks on postoperative opioid consumption after lumbar microsurgery. The secondary aim is to compare opioid-related side effects (such as nausea, vomiting, respiratory depression, etc.) and postoperative NRS pain scores between the groups.

Eligibility criteria

Qualifiers

Patients aged 18 to 80 years

American Society of Anesthesiologists (ASA) physical status I to III

scheduled for lumbar microdiscectomy surgery

Disqualifiers

Known allergy to local anesthetics

Any other significant drug allergies related to the study interventions

Pregnancy

Pre-existing psychiatric or neurological disorders

Trial design

Treatments tested in this trial

  • Standard Analgesia (No Block)
  • Thoracolumbar Interfascial Plane (TLIP) Block
  • Quadro Iliac Plane Block

Treatment groups

90 Participants
are divided into 3 treatment groups

Sponsors and collaborators